Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wangxiong Hu

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Journal of Oncology|September 22, 2022
Hypoxia Confers Tumor with a Higher Immune Infiltration but Lower Mutation Burden in Gastrointestinal CancerJunjie Hu, Wangxiong Hu, Yanmei Yang
DNA and Cell Biology|September 10, 2020
Hypermethylation of <i>DRD5</i> Promoter Is a Biomarker Across 12 Cancer TypesRui Bai, Jinzhi Mei, Wangxiong Hu
Journal of Cellular and Molecular Medicine|November 2, 2018
Deciphering molecular properties of hypermutated gastrointestinal cancerWangxiong Hu, Yanmei Yang, Weiting Ge, et al.
Cancer Genetics|November 12, 2015
Tumor heterogeneity uncovered by dynamic expression of long noncoding RNA at single-cell resolutionWangxiong Hu, Tingzhang Wang, Yanmei Yang, et al.
Biochemical and Biophysical Research Communications|August 24, 2014
CPuORF correlates with miRNA responsive elements on protein evolutionary ratesWangxiong Hu, Tingzhang Wang, Yanmei Yang, et al.
Frontiers in Oncology|December 17, 2020
Hypoxia Correlates With Poor Survival and M2 Macrophage Infiltration in Colorectal CancerLina Qi, Jiani Chen, Yanmei Yang, et al.
Heliyon|January 9, 2023
A pretreatment transcriptomic signature that predicts outcomes of immunotherapy in melanomaJunjie Hu, Bei Liu, Wangxiong Hu, et al.
Oncotarget|August 25, 2016
Association mining of mutated cancer genes in different clinical stages across 11 cancer typesWangxiong Hu, Xiaofen Li, Tingzhang Wang, et al.
Oncotarget|December 31, 2016
Pan-organ transcriptome variation across 21 cancer typesWangxiong Hu, Yanmei Yang, Xiaofen Li, et al.
Oncotargets and Therapy|July 18, 2022
Association Mining Identifies MAL2 as a Novel Tumor Suppressor in Colorectal CancerKailai Wang, Yanmei Yang, Shu Zheng, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Journal of Oncology|September 22, 2022
Hypoxia Confers Tumor with a Higher Immune Infiltration but Lower Mutation Burden in Gastrointestinal CancerJunjie Hu, Wangxiong Hu, Yanmei Yang
DNA and Cell Biology|September 10, 2020
Hypermethylation of <i>DRD5</i> Promoter Is a Biomarker Across 12 Cancer TypesRui Bai, Jinzhi Mei, Wangxiong Hu
Journal of Cellular and Molecular Medicine|November 2, 2018
Deciphering molecular properties of hypermutated gastrointestinal cancerWangxiong Hu, Yanmei Yang, Weiting Ge, et al.
Cancer Genetics|November 12, 2015
Tumor heterogeneity uncovered by dynamic expression of long noncoding RNA at single-cell resolutionWangxiong Hu, Tingzhang Wang, Yanmei Yang, et al.
Biochemical and Biophysical Research Communications|August 24, 2014
CPuORF correlates with miRNA responsive elements on protein evolutionary ratesWangxiong Hu, Tingzhang Wang, Yanmei Yang, et al.
Frontiers in Oncology|December 17, 2020
Hypoxia Correlates With Poor Survival and M2 Macrophage Infiltration in Colorectal CancerLina Qi, Jiani Chen, Yanmei Yang, et al.
Heliyon|January 9, 2023
A pretreatment transcriptomic signature that predicts outcomes of immunotherapy in melanomaJunjie Hu, Bei Liu, Wangxiong Hu, et al.
Oncotarget|August 25, 2016
Association mining of mutated cancer genes in different clinical stages across 11 cancer typesWangxiong Hu, Xiaofen Li, Tingzhang Wang, et al.
Oncotarget|December 31, 2016
Pan-organ transcriptome variation across 21 cancer typesWangxiong Hu, Yanmei Yang, Xiaofen Li, et al.
Oncotargets and Therapy|July 18, 2022
Association Mining Identifies MAL2 as a Novel Tumor Suppressor in Colorectal CancerKailai Wang, Yanmei Yang, Shu Zheng, et al.
Pageof 5